AstraZeneca and Oxford University on Wednesday acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine. In the low-dose group, AstraZeneca said, the vaccine appeared to be 90 per cent effective. WATCH | The hidden opportunity in AstraZeneca's vaccine error:The hidden opportunity in AstraZeneca’s vaccine error News Video 1:04 The manufacturing error in AstraZeneca's COVID-19 trial vaccine may ultimately lead to a better version, says Dr. Matthew Oughton, an infectious disease specialist at Montreal's Jewish General Hospital. Some 2,741 people received a half dose of the vaccine followed by a full dose, AstraZeneca said. A laboratory technician works at the mAbxience biopharmaceutical company in Garin, Argentina, which has agreed to make the AstraZeneca vaccine if approved.

Source: CBC News November 26, 2020 02:00 UTC